PLT012 is a first-in-class anti-CD36 monoclonal antibody and the first metabolic checkpoint therapy designed to reprogram the tumor microenvironment Phase 1 trial expected to begin in 1Q 2026 DOVER, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback